(RTTNews) - Amgen (AMGN) said that the U.S. Food and Drug Administration approved Imdelltra or tarlatamab-dlle for the treatment of adult patients with extensive-stage small cell lung cancer or ES-SCLC with disease progression on or after platinum-based
FDA approves Gilotrif™ (afatinib) as treatment for lung cancerBoehringer Ingelheim
The US Food and Drug Administration (FDA) todayapprovedthe combination ofnivolumab(Opdivo, Bristol-Myers Squibb) plusipilimumab(Yervoy, Bristol-Myers Squibb) as first-line treatment for patients with metastatic non-small-cell lung cancer (NSCLC) whose tumors express PD-L1 (≥ 1%). Use is limited...
Nivolumab(Opdivo, Bristol-Myers Squibb Company) is the first immunotherapy to be available for use in the treatment of lung cancer. The drug has just been approved by the US Food and Drug Administration (FDA) for use in patients with advanced/metastatic squamous non–small cell lung cancer (...
The US Food and Drug Administration (FDA) today expanded the approved use ofnivolumab(Opdivo, Bristol-Myers Squibb) to include the treatment of patients with metastatic nonsquamous, non-small-cell lung cancer (NSCLC) whose disease progressed during or after platinum-based chemotherapy. ...
In lung cancer, trials of new targets were among the most clinically relevant presented at the 2019 annual meeting of the American Society of Clinical Oncology (ASCO). Several emerging targets had data so compelling that they now deserve to shape our treatment decisions, because there are agents...
The FDA approval is for treating aduults with unresectable, Stage III EGFR-mutated non-small cell lung cancer or NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy. In the trial, Tagrisso reduced the risk of disease progression ...
Lung cancer is the primary cause of mortality in the United States and around the globe. Therapeutic options for lung cancer treatment include surgery, radiation therapy, chemotherapy, and targeted drug therapy. Medical management is often associated wit
pivotal trial in advanced small cell lung cancer to receive full fda approval of the drug. the company is also testing tarlatamab for treating patients with earlier-stage small cell lung cancer. if those studies prove successful, wall street analysts have said tarlatamab could represent an annua...
Johnson & Johnson made a pair of announcements Tuesday: Federal Drug Administration (FDA) approval of a new lung cancer treatment and an acquisition. The FDA approved a pair of drugs as a form of chemotherapy-free lung cancer treatment after a Phase 3 clinical trial showed the drugs reduce...